Janet Huffman
Equibles does not estimate personal net worth.
Get an email with a short summary when Oragenics Inc publishes a filing, an earnings call transcript or a press release.
Get OGEN alertsAbout Janet Huffman
Janet Huffman is recorded as CEO at Oragenics Inc (OGEN) since May 2, 2025 and CFO at Oragenics Inc (OGEN). Oragenics Inc reported in an 8-K filed May 2, 2025 that Janet Huffman was appointed Chief Executive Officer, effective May 2, 2025. Oragenics Inc reported in an 8-K filed January 17, 2025 that Janet Huffman was appointed Interim Chief Executive Officer, effective January 16, 2025. Oragenics Inc reported in an 8-K filed December 16, 2024 that Janet Huffman was appointed Interim Principal Executive Officer and President, effective December 16, 2024. Equibles holds 4 filed executive changes naming Janet Huffman; each is listed under recent activity with its source filing. The proxy statement of Oragenics Inc reports total compensation of $609,157 for Janet Huffman in fiscal 2025, including a base salary of $285,801. Disclosed compensation is on record for 3 fiscal years. Oragenics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Oragenics Inc includes Dr. Alan (CEO), Dr. Alan Joslyn (CEO), Kimberly M. Murphy (CEO) and 7 others.
“On May 2, 2025, the Board of Directors (the "Board") of Oragenics, Inc. (the "Company") appointed Janet Huffman, the Company's Chief Financial Officer and Interim Chief Executive Officer, to serve as the Company's Chief Executive Officer, in addition to continuing to serve as its Chief Financial Officer, and, in connection therewith, effective May 2, 2025, the Company entered into an Executive Employment Agreement with Ms. Huffman (the "Employment Agreement").”
“On January 16, 2025, the Board of Directors (the “Board”) of Oragenics, Inc. (the “Company”) appointed Ms. Janet Huffman, the Company’s Chief Financial Officer and Interim Principal Executive Officer, to also serve as the Company’s Interim Chief Executive Officer effective as of January 16, 2025”
Affiliation history
-
Current
2025-05-02–present
-
Oragenics Inc (OGEN)
SEC 8-K
Current2024-12-16–present
-
Current
Company network
Leadership on record at Oragenics Inc
- Dr. Alan CEO
- Dr. Alan Joslyn CEO
- Kimberly M. Murphy CEO
- Michael Redmond CEO
- Charles L. Pope Chairman
- Charlie Pope Chairman
- John Spencer CFO
- Kimberly Murphy CFO
- Michael O. Sullivan CFO
- Alan W. Dunton Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Oragenics Inc (OGEN) | Chief Financial Officer, Chief Executive Officer | $285,801 | $609,157 |
| 2024 | Oragenics Inc (OGEN) | Chief Financial Officer, Interim Chief Executive Officer | $250,000 | $363,700 |
| 2023 | Oragenics Inc (OGEN) | Chief Financial Officer, Interim Chief Executive Officer | $208,333 | $420,346 |